Abstract
Mild cognitive impairment (MCI) is a clinical syndrome thought to represent the transition between normal function and dementia. This review describes data that support the existence of such a transitional phase, outlines the heterogeneity of MCI and how that has influenced the evolving concept of MCI, and discusses the impact of heterogeneity on recent MCI clinical trials.
MeSH terms
-
Alzheimer Disease / diagnosis
-
Alzheimer Disease / psychology
-
Cholinesterase Inhibitors / therapeutic use
-
Clinical Trials as Topic / statistics & numerical data
-
Cognition Disorders / diagnosis*
-
Cognition Disorders / drug therapy
-
Cognition Disorders / psychology
-
Dementia / diagnosis*
-
Dementia / psychology
-
Donepezil
-
Humans
-
Indans / therapeutic use
-
Models, Psychological
-
Neuropsychological Tests / statistics & numerical data
-
Piperidines / therapeutic use
-
Syndrome
-
Terminology as Topic
-
Treatment Outcome
Substances
-
Cholinesterase Inhibitors
-
Indans
-
Piperidines
-
Donepezil